Close Menu

NEW YORK – Tempus on Monday announced a strategic collaboration with Janssen Research & Development in oncology clinical development programs and data science.

For this collaboration, Tempus said that it is developing a predictive machine-learning model to improve enrollment in biomarker-driven clinical trials for Janssen R&D, a unit of Johnson & Johnson's Janssen Pharmaceutica. According to Chicago-based Tempus, Janssen is looking for a method to speed up the identification of patients with specific tumor features that match the requirements of trials.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

In a letter, about two dozen researchers criticize the World Health Organization investigation into the origins of SARS-CoV-2 and call for a new inquiry, the Wall Street Journal reports.

National Geographic reports that nine great apes at the San Diego Zoo have been vaccinated against SARS-CoV-2.

Janet Woodcock, the acting commissioner of the US Food and Drug Administration, speaks with NPR about SARS-CoV-2 testing and vaccines in the US.

In Science this week: genetic study of kidney fibrosis implicates the SOX9-NAV3-YAP1 axis.